Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

CTP-543 is generally safe for treating alopecia areata.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

This review discusses the evidence supporting Janus kinase inhibitors for alopecia areata and highlights ongoing optimism as phase 3 trials begin, with no new clinical results reported.

This study found that oral Janus kinase inhibitors were effective in treating alopecia areata, with a clinical response rate of 48.3%, though further research is needed to assess long-term effects.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.

This review discusses the development of Janus kinase inhibitors for dermatologic diseases and reports no new results; the authors note the need for further research on their efficacy and safety.

In this study of seven randomized clinical trials, JAK inhibitors were associated with improved hair regrowth outcomes in alopecia areata patients compared to placebo, with oral administration being more effective than external application, though longer trials are needed to confirm safety and effectiveness.

In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.

This review examines the mechanisms of Janus kinase inhibitors in treating alopecia areata and evaluates their efficacy and safety, but reports no new clinical results.

In this study, health state utility values revealed a significant impact on quality of life for patients with alopecia areata, particularly those with more extensive hair loss.

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

This study found that JAK inhibitors effectively improve alopecia areata outcomes, as indicated by SALT scores, but they were associated with an increased risk of adverse effects, with 921 out of 1508 patients experiencing adverse reactions.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

This study reviewed the safety of JAK inhibitors for alopecia areata, finding that common side effects included headache and acne, with varying risks for respiratory infections and no increased risk of serious adverse events.

This review discusses the role of Janus-kinase inhibitors in treating severe atopic dermatitis and alopecia areata, presenting case studies that show their efficacy and calling for further research on long-term effectiveness and safety.

This study indicates that the EQ-5D-5L may not effectively capture the burden of alopecia areata on patients' health-related quality of life, and suggests that alternative measures might better assess treatment benefits related to hair regrowth.

This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.

This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.

This source reports that based on international Phase 3 trial results, the JAK1/2 inhibitor baricitinib was approved in Japan in June 2022 for treating extensive alopecia areata, offering a potentially useful treatment option.

This paper reviews current and developing treatments for severe alopecia areata but reports no new clinical findings; the authors highlight the need for standardized treatment protocols.

This article reviews the role of the JAK-STAT pathway in inflammatory skin diseases and considers the therapeutic benefits of JAK inhibitors, presenting them as promising treatments but reports no new experimental results.

This chapter reviews current and emerging pharmacological treatments for alopecia, noting that the FDA's classification of alopecia as a cosmetic disease has limited drug development and led to off-label use of potentially dangerous compounds.

This review explores the current treatments for different types of alopecia, emphasizing the need for well-designed clinical trials and highlighting that most therapies are used off-label, as only androgenetic alopecia has FDA-approved drugs.